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Abstract 
Background: Breast cancer is the second leading cause of cancer death worldwide. Nanotechnology approaches 
can overcome the side effects of chemotherapy as well as improve the efficacy of drugs. Dendrimers are nanometric 
size polymers which are suitable as drug delivery systems. To the best of our knowledge, studies on the application of 
PAMAM G4.5 (polyamidoamine half generation 4) dendrimers as potential drug delivery systems in breast cancer have 
not been reported. In this work we developed a PAMAM G4.5 dendrimer containing FITC (fluorescein isothiocyanate) 
dye to study their uptake by murine breast cancer cells and BALB/c mice breast tumors.
Results: We performed a reaction between FITC and PAMAM G4.5 dendrimers which were previously derivatized 
with piperazine (linker molecule), characterized them by 1H NMR (proton nuclear magnetic resonance) spectroscopy 
and MALDI‑TOF (matrix‑assisted laser desorption/ionization‑ time‑of‑flight) mass spectrometry. The experimental 
data indicated that 2 FITC molecules could be bound covalently at the PAMAM G4.5 dendrimer surface, with 17 FITC 
molecules probably occluded in PAMAM dendrimers cavity. PAMAM‑FITC dendrimer (PAMAM G4.5‑piperazinyl‑FITC 
dendrimer) size distribution was evaluated by DLS (dynamic light scattering) and TEM (transmission electron micros‑
copy). The nanoparticle hydrodynamic size was 96.3 ± 1.4 nm with a PdI (polydispersion index) of 0.0296 ± 0.0171, 
and the size distribution measured by TEM was 44.2 ± 9.2 nm. PAMAM‑FITC dendrimers were neither cytotoxic in 4T1 
cells nor hemolytic up to 24 h of incubation. In addition, they were uptaken in vitro by 4T1 cells and in vivo by BALB/c 
mice breast tumors. PAMAM G4.5‑piperazinyl‑FITC dendrimer intracellular distribution was observed through histo‑
logic analysis of the tumor by laser confocal microscopy.
Conclusion: These results indicate that PAMAM G4.5 dendrimers enter tumor tissue cells, being good candidates to 
be used as antitumor drug delivery systems for breast cancer treatment and diagnosis.
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Background
Breast cancer remains the most common invasive can-
cer in women and is the second leading cause of cancer 
death worldwide [1–4]. Chemotherapy of solid tumors, 
including breast cancer, is linked to several side effects 
[5]. Nanotechnology provides the possibility of creating 
delivery systems that reduce the unwanted side effects 
of systemic delivery, increasing tumor accumulation and 
improving efficacy [6]. The EPR effect (enhanced perme-
ability and retention effect) is responsible for the afore-
mentioned advantages. The EPR effect arises due to 
differences between the blood vessels surrounding the 
tumors and those of normal tissues [7]. Blood vessels in 
tumors are defective and the endothelial cells in the ves-
sels are poorly aligned [8]. Owing to the permeability 
of tumor blood vessels, nanosized vehicles would pass 
through into the tumor but not into healthy tissues [7]. 
The EPR effect also allows nanovehicles to accumulate in 
the tumor site due to poor lymphatic drainage [4, 8, 9]. 
Therefore, EPR effect is an important pharmacokinetic 
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principle to take into account in the design of drug 
delivery nanosystems [10]. Since its description by Mat-
sumura and Maeda in 1986, several experimental evi-
dences have confirmed the existence of this effect in solid 
tumors [11–14].
PAMAM dendrimers are branched macromolecules 
with multiple end-groups that can be functionalized with 
different molecules, including drugs [15]. Drugs can also 
be encapsulated into dendrimer cavities which makes 
them suitable as drug delivery systems [16, 17].
In order to use dendrimers as drug delivery systems 
for cancer therapy, it is important to know if they are 
uptaken by the tumor. There are several studies report-
ing the uptake of full generation dendrimers (cationic 
dendrimers) in different cell lines [18–21]. This could 
be attributed to the fact that full generation dendrimer 
labeling is simpler than half generation dendrimer (ani-
onic) labeling. However, recent evidence underlines the 
influence of charge in dendrimer cytotoxicity, being full 
generation dendrimers more toxic than half generation 
dendrimers [22–24]. This toxicity is related to dendrim-
ers surface charge; positively charged dendrimers are 
more toxic than negative charged dendrimers [25–27]. 
Full generation dendrimers become biocompatible when 
functionalized with certain molecules because of neutral-
ization of positive charges [28].
There are few reports on half generation PAMAM 
dendrimers in cancer applications [8, 29]. For instance, 
Kirkpatrick et al. [8] in 2011, evaluated anionic half gen-
eration (G3.5–G6.5) PAMAM dendrimers as delivery 
vehicles of cisplatin for ovarian cancer treatment [8] and 
Morgan et  al. in 2006, employed a polyester G4.5 den-
drimer composed of glycerol and succinic acid to deliver 
antitumor camptothecins in cancer cell lines [30]. On the 
other hand, Kitchens et al. studied the uptake of PAMAM 
dendrimers of half generation (G1.5–G3.5) in Caco-2 
cells and they conjugated the dendrimers with FITC to 
this end. These researchers employed an ethylenediamine 
moiety as linker group and did not describe spectro-
scopic characterization of the prepared fluorescent den-
drimers [31]. A recent work from Yuan et  al. 2011, has 
conjugated PAMAM G4.5 dendrimers with AAF (5-(ami-
noacetamido)fluorescein), to track transbuccal transport 
of these dendrimers as potential central nervous system 
therapeutic nanoparticles [32]. They compared the per-
meability of AAF labeled PAMAM G4.5 dendrimers with 
FITC labeled PAMAM G4 dendrimers. They showed that 
AAF-labeled PAMAM G4.5 dendrimers were less perme-
able than FITC-labeled PAMAM G4 dendrimers. This 
result was consistent with the study of Kitchens et  al. 
[31], who showed that cationic PAMAM dendrimers can 
gain enhanced transport by causing opening of epithelial 
tight junctions and toxicity effects. These authors did 
not study these dendrimers as potential nanovehicles 
for drug delivery in breast cancer. Noteworthy, stud-
ies related to PAMAM G4.5 dendrimers cell uptake and 
intracellular distribution were not found in the literature, 
nor was the use of PAMAM G4.5 dendrimers as potential 
drug delivery nanosystems in breast cancer.
According to the information previously described 
regarding PAMAM dendrimers, dendrimer generation 
and dendrimer charge are physicochemical important 
parameters to be considered in the selection of the type 
of dendrimer to be used for a certain application. Thus, 
taking into account the absence of studies of PAMAM 
G4.5 dendrimers as potential drug delivery nanosystems 
in breast cancer and that positive charged dendrimers are 
more toxic than negative charged dendrimers, PAMAM 
G4.5 carboxylate dendrimers were selected. In the pre-
sent work, we characterized the in  vitro and in  vivo 
uptake of PAMAM G4.5 carboxylate dendrimers in 4T1 
tumor cells, showing for the first time that these den-
drimers have a great potential as drug delivery nanosys-
tems for breast cancer treatment and diagnosis.
Results and discussion
Synthesis and characterization of PAMAM 
G4.5‑piperazinyl‑FITC dendrimer
Recently, our group labeled directly PAMAM G4 den-
drimers with FITC (fluorescein isothiocyanate) [15]. 
Fluorescein is one of the most common fluorophores 
employed in nanoparticle uptake studies. As the car-
boxylic acids groups in PAMAM G4.5 dendrimers are 
not able to directly bind to FITC, an adequate linker is 
required to this end. N-Monoprotected piperazine was 
used as the linker moiety; it is a bifunctional molecule 
with a free amine group and an amine group covalently 
bonded to a tert-butyloxycarbonyl protecting group (N-
Boc). The dendrimer was first bound to the free amine 
group of piperazine via an amide moiety, generating 
PAMAM G4.5-N-Boc-piperazinyl dendrimer, and after 
N-Boc deprotection, it was bound to FITC as described 
in the “Methods” section.
The intermediate PAMAM G4.5-N-Boc-piperazinyl 
dendrimer was characterized by 1H NMR at 303  K in 
D2O, because this intermediate product was poorly sol-
uble in other solvents like MeOH-d4 or DMSO-d6. The 
signal at 1.35 ppm (H, Fig. 1) in 1H NMR spectrum that 
corresponds to the protons of t-butyl methyl groups of 
N-Boc-piperazine, confirms the formation of the amide. 
Besides, the signal at 1.34 ppm (H, Fig. 1) corresponds to 
the protons of methylene groups at the core of PAMAM 
G4.5 dendrimers (Fig.  1). According to the integration 
of the signals of 1H NMR spectra, it can be confirmed 
Page 3 of 12Oddone et al. J Nanobiotechnol  (2016) 14:45 
that piperazine was covalently bonded to PAMAM G4.5 
dendrimers in an N-Boc-piperazine: PAMAM G4.5 den-
drimer ratio of 2:1 (Fig. 1).
After N-Boc group elimination, using trifluoro-
acetic acid, the subsequent reaction of the piperazinyl-
dendrimer derivative with FITC was performed. This 
synthetic procedure was performed five times. The 
PAMAM-FITC dendrimers were characterized, by 
1H NMR at 303  K in D2O, owing to the final product 
was poorly soluble in other solvents like MeOH-d4 or 
DMSO-d6.
In all the cases (n =  5) the 1H NMR spectrum of the 
final desired product, PAMAM G4.5-piperazinyl-FITC 
dendrimer, presented an unexpectedly larger protons-
integration number in the fluorescein region (6.0–
8.0  ppm) (Fig.  2a). The synthesis procedure included 
extensive washing, of the derivatized dendrimer with 
water, and centrifugation with Microcon® (cutoff of 
10  kDa) in order to remove un-reacted FITC [33–37]. 
According to the structure of the intermediate PAMAM 
G4.5-N-Boc-piperazinyl, it was anticipated that only 
two units of FITC had been incorporated. However, the 
experimental 1H NMR data indicated, in all cases (n = 5), 
that near to 19 FITC molecules were added to PAMAM 
dendrimers with 17 of them probably occluded in non-
covalent form.
In order to confirm this last observation, we also char-
acterized the final products by MALDI-TOF mass spec-
trometry (Fig. 2b) observing a signal corresponding to the 
m/z of PAMAM G4.5 and to the m/z of PAMAM G4.5-
piperazinyl-FITC dendrimer with up to 19 molecules of 
FITC. For these large molecules, the signals are not well 
resolved, but a general molecular weight distribution can 
be observed [38]. The FITC molecules could be cova-
lently bound through the piperazine linker or occluded 
in the dendrimer. Because the synthetic dendrimer-
piperazinyl intermediate presented a 1:2 stoichiometry 
(dendrimer:piperazine), only 2 FITC molecules could 
be bound covalently in the final product. The remaining 
FITC molecules would be non-covalently bound to the 
dendrimer. Figure  2b shows the MALDI-TOF experi-
mental signal and the calculated signal for the dendrimer 
with 2, 14, 17 and 19 molecules of FITC. On the other 
hand, the FITC release from PAMAM G4.5-piperazinyl-
FITC dendrimers was studied in aqueous solution. FITC 
encapsulated into dendrimers resulted to be very stable 
since the compound showed a low percentage of FITC 
release at 24 and 48 h (4.4 and 5.2 %, respectively). This 
means that this compound was stable at least for 48 h in 
this condition (Fig. 3).
The molecular encapsulation of FITC could be the 
result from hydrogen bonding interactions between the 
Fig. 1 1H NMR of PAMAM G4.5‑N‑Boc‑piperazinyl dendrimers. This spectrum was acquired in D2O at 303 K (number of scans 64)
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phenol, the isothiocianate, and the lactone moieties of 
this and the amines and amides functionalities of the 
polymeric amidoamine feature of PAMAM G4.5 [39]. No 
electrostatic bonding could be also considered as respon-
sible, at least in part, of the encapsulation of fluorescent 
probe. In this case, one could speculate that the aromatic 
regions of FITC interact positively via van der Waals 
forces with the hydrocarbon backbone of PAMAM [40].
PAMAM G4.5‑piperazinyl‑FITC dendrimer size
The nanoparticle size distribution of PAMAM G4.5-
piperazinyl-FITC dendrimer, was performed by DLS 
and TEM. PAMAM-FITC dendrimers hydrodynamic 
size was 96.3 ±  1.4  nm with a PdI of 0.0296 ±  0.0171. 
We also measured nanoparticle size by TEM, and could 
determine a mean PAMAM-FITC dendrimer diameter 
of 44.2 ±  9.2  nm (Fig.  4a, b). DLS provides the average 
hydrodynamic size of particles in a solution, being this 
measure directly related to the diffusive motion of the 
particles [41]. Thus, the size measured by DLS includes 
the solvent layers around the individual nanoparticles. 
These solvent layers are not present in TEM images of 
the nanoparticles due to previous sample drying [42]. 
Both techniques are complimentary and TEM gives 
Fig. 2 Structural characterization of PAMAM‑FITC dendrimers. a 1H NMR spectrum was acquired in D2O at 303 K (number of scans 64). b MALDI‑TOF 
mass spectrometry. Experimental data (green trace) and calculated spectra (black trace)
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information of nanoparticle structure as well. However, 
TEM suffered from the small sampling size involved 
[41]. The significant difference in size of PAMAM-FITC 
dendrimer measured by TEM and DLS, could be attrib-
uted to the presence of dendrimer solvent layers attached 
during DLS measurement. In addition, since the scatter-
ing intensity is directly proportional to the sixth power 
of the particle radius, DLS technique is extremely sen-
sitive towards the presence of small aggregates [41]. 
Nevertheless, we do not think that dendrimer aggrega-
tion occurred due to the fact that polydispersion index 
obtained was close to zero.
Cytotoxicity and hemolytic studies of PAMAM‑FITC 
dendrimer
The cytotoxicity of PAMAM G4.5-piperazinyl-FITC den-
drimer was evaluated in 4T1 cells. These cells were incu-
bated for 24  h with PAMAM- FITC dendrimer and no 
cytotoxicity was observed at the time period and concen-
trations assayed (Fig. 5).
Other authors who have evaluated the influence of 
surface modification in cytotoxicity of other type of 
PAMAM dendrimers, made these studies employing 
higher concentrations and different incubation times 
than the ones used in our work [19, 28].
PAMAM G4.5-piperazinyl-FITC dendrimers showed 
to be not cytotoxic up to 50  µM (maximal concentra-
tion tested). Anionic half generation dendrimers have 
previously been shown to be significantly less cytotoxic 
compared with cationic full generation dendrimers [43]. 
Kirkpatrick et  al. [8], tested in  vitro cytotoxicity of ani-
onic half generation PAMAM dendrimers 3.5–6.5 and 
showed no cytotoxicity (IC50  >  100  μM). On the other 
Fig. 3 Release study of FITC from PAMAM G4.5‑piperazinyl‑FITC. 
The release of the encapsulated FITC study was made in PBS 1× at 
37 °C, as described in “Methods” section, for the following periods of 
incubation: 0, 6, 18, 24 and 48 h. The fluorescence of the collected 
samples was measured in a plate reader with excitation and emission 
wavelength of 495 and 525 nm, respectively. Percentages of FITC 
released were calculated and graphed
Fig. 4 Size and morphology of PAMAM G4.5‑piperazinyl‑FITC. a Representative TEM image of nanoparticles stained with uranyl acetate. b Size 
distribution histogram from TEM images. Particle size was measured according to “Methods” section
Page 6 of 12Oddone et al. J Nanobiotechnol  (2016) 14:45 
hand, they also showed that 37 molecules of cisplatin 
could be bound to PAMAM G4.5 dendrimers [8]. Thus, 
we can speculate that if PAMAM G4.5-piperazinyl-FITC 
dendrimers could bind or encapsulate similar number of 
anti- tumor molecules per dendrimer, a dendrimer con-
centration of 50 µM would be sufficient enough to deliver 
drugs acting in the nM or few µM ranges.
On the other hand, hemolytic studies showed that the 
incubation of red blood cells with PAMAM G4.5-piper-
azinyl-FITC dendrimers did not caused hemolysis. Thus, 
the compound showed to be neither cytotoxic nor hemo-
lytic at 50 μM up to 24 h (Figs. 5, 6).
In vitro cellular uptake of PAMAM G4.5‑piperazinyl‑FITC 
dendrimers
The cellular uptake of PAMAM G4.5-piperazinyl-FITC 
dendrimer was evaluated in 4T1 cells at 24 h of incuba-
tion. The dendrimers were uptaken by the cells (Fig.  7). 
Since another membrane selective dye was not used 
in the study, we cannot rule out the possibility that the 
dendrimer could be located also in the cell plasma mem-
brane and in cell nuclei. However, most of the observed 
signal appears to be perinuclearly located (Fig.  7). Pre-
viously, our group had obtained experimental evidence 
that the distribution of PAMAM G4-FITC dendrimers 
in primary cultured human myometrial cells was perinu-
clear [15] and several reports have shown that intracel-
lular distribution of different type of dendrimers was also 
perinuclear [44, 45].
Additionally, as previously mentioned, the result of 
the stability study of PAMAM G4.5-piperazinyl-FITC 
dendrimers showed that up to 24 h, no significant release 
of FITC was detected (Fig.  3). This result suggests that 
the fluorescence signal detected inside the cells by confo-
cal microscopy is from the dendrimer linked FITC that 
were uptaken by the cells and not by free released FITC.
Ex vivo fluorescence imaging of BALB/c mice bearing 
4T1 tumor treated with PAMAM G4.5‑piperazinyl‑FITC 
dendrimer and tissue slide analysis
To the best of our knowledge, the present work is the 
first to investigate the uptake of PAMAM G4.5 den-
drimers by mammary tumors. This study was made 
by ex  vivo imaging through intravenous injection of 
PAMAM G4.5-piperazinyl-FITC dendrimer in BALB/c 
mice with 4T1 induced tumor. This tumor model resem-
bles to that of human breast cancer stage IV, which is 
the metastatic stage [46]. Ex vivo imaging study was per-
formed, because developed compound was labeled with 
FITC. FITC is a weak dye for in vivo study as the emit-
ted fluorescence cannot cross the skin and hair of mice. 
However, the principal objectives of the present work 
could be achieved with the use of this dye. At 24 h post-
injection, certain organs were excised and ex vivo images 
were taken. PAMAM G4.5-piperazinyl-FITC den-
drimer showed a slightly hepatic uptake, renal excretion 
and tumor uptake (Fig.  8a–c). Renal depuration of this 
dendrimer is probably a result of its molecular weight 
(~34 kDa) which is below the threshold of renal filtration 
of 40–60  kDa. Tumor uptake may be due to enhanced 
permeability and retention effect (EPR effect), in which 
nanoparticles tend to accumulate more in tumor tissue 
Fig. 5 Cell viability study of PAMAM G4.5‑piperazinyl‑FITC on 4T1 
cells. This study was carried out by MTT assay at different concentra‑
tions at 24 h of incubation as described in “Methods” section. Viability 
percentages and their error bars are expressed as mean ± SD and 
represent the result of three experiments. No cytotoxicity from FITC‑
conjugated PAMAM G4.5 dendrimers was observed on this cell line
Fig. 6 Hemolytic study of PAMAM G4.5‑piperazinyl‑FITC. The study 
was performed by incubating red blood cells from dog with 5 or 
50 µM dendrimer concentrations at 4 and 24 h. The percent hemoly‑
sis was calculated considering the positive control of hemolysis (SDS 
2 %) as 100 % of hemolysis
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than in the other tissues [7, 47–51]. We clearly observed 
that PAMAM G4.5 dendrimer was uptaken by tumor 
cells (Fig. 9). Thus, the developed compound labeled with 
FITC showed its capacity to be uptaken by the tumor. It 
could be interesting in the near future to label PAMAM 
G4.5-piperazinyl with Cy3 or Cy5 instead of FITC and try 
to perform in vivo imaging (bio-distribution) of the com-
pound in this animal model. 
Conclusions
In order to evaluate half generation PAMAM dendrimers 
as possible vehicles in breast cancer, we developed and 
characterized PAMAM G4.5-piperazinyl-FITC dendrim-
ers. These dendrimers were not cytotoxic in 4T1 tumor 
cells and were uptaken by these cells. Most importantly, 
when dendrimers were administered to BALB/c mice 
bearing 4T1 tumors, tumor uptake was observed. Hence, 
Fig. 7 Cellular uptake of PAMAM G4.5‑piperazinyl‑FITC by 4T1 cells at 24 h incubation. a FITC stain (green), b DAPI counterstain (sky blue) and c 
merge. As it can be seen from the image, PAMAM G4.5‑piperazinyl‑FITC dendrimers were uptake by the cells. Magnification: 80×. Scale bar 20 μm
Fig. 8 Ex vivo fluorescence imaging of BALB/c mice with 4T1 tumor and tumor tissue analysis. a Analyzed organs. The image was taken from 
organs of a control animal. b Ex vivo fluorescence image of organs from control animal. c Ex vivo fluorescence images of organs from PAMAM‑FITC 
dendrimer‑injected animals, 24 h post‑injection. The images were taken at λexc: 480 nm and λem: 535 nm
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the results obtained by employing 4T1 tumor cells and 
mice with tumors induced with these cells, further sug-
gest that the nanosystem enters tumor tissue cells.
One of the principal objectives of the present work was 
to verify that the developed nanosystem was able to enter 
tumor cells and be uptaken by the tumor. With the nano-
system PAMAM G4.5-piperazinyl-FITC dendrimer these 
objectives were accomplished.
PAMAM G4.5 dendrimers are good candidates to be used 
as antitumor drug delivery systems for breast cancer 
treatment or diagnostics
Additionally, it is possible to employ PAMAM G4.5-
N-Boc-piperazinyl dendrimers to generate other fluores-
cent imaging agents for in vivo studies of tumors. In this 
case, it would be necessary to bind these dendrimers with 
fluorophores that operate in the far-red and near-infrared 
region of electromagnetic spectrum (NIR fluorophores) 
[52]. The low absorption of light exhibited by tissues in 
this spectral window, makes it possible for the light to 
cross various centimeters [52]. The emitted FITC fluores-
cence cannot cross the skin and hair of mice, and there-
fore cannot be detected. The AAF fluorophore previously 
used to label PAMAM G4.5 dendrimers [32], which its 
excitation and emission wavelengths are 492  ±  3 and 
514  ±  4  nm, respectively, exhibits the same limitations 
as FITC. Kim et  al. 2013. conjugated the fluorophores 
Cy3 or Cy5 to PAMAM G5 and G6 dendrimers as imag-
ing agents and as previously mentioned these could be a 
good option in imaging [53].
Methods
Synthesis of PAMAM G4.5‑piperazinyl‑FITC dendrimers
Methanol from PAMAM G4.5 dendrimers (Sigma 
Aldrich Co. 5 % w/v in methanol) was eliminated by vac-
uum evaporation (BUCHI). After that, the activation of 
the carboxyl groups of the dendrimers was made by EDC 
(1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) addi-
tion (dissolved in PBS 1x) to previously dried dendrim-
ers. The EDC:dendrimer ratio used was 30:1. This mixture 
Fig. 9 Tumor tissue imaging by LCM after 24 h PAMAM G4.5‑piperazinyl‑FITC dendrimer post‑injection. a 3D reconstruction of tumor tissue section. 
PAMAM G4.5‑piperazinyl‑FITC dendrimers are shown in green and DAPI in blue. b, c and d 2D images of a slide from the 3D reconstruction of tissue 
section in part A, showing FITC stain, DAPI counterstain and merge, respectively. Magnification: 63×. Scale bar 10 µm
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was incubated for 30 min. N-Boc-piperazine dissolved in 
DMSO (30:1 N-Boc-piperazine:dendrimer ratio) was then 
added to the mixture and incubated for 3 h in the same 
conditions. The mixture was purified by gel filtration to 
eliminate unreacted N-Boc-piperazine and fractions of 
500 μL were collected and controlled by thin layer chro-
matography (TLC). The fractions 5–9 were joined and 
lyophilized. According to 1H NMR analysis the rest of 
the fractions (1–4 and 10-end) did not correspond to the 
desired product. This procedure was performed five times 
and the results obtained were all the same.
The obtained intermediate, G4.5-piperazinyl-Boc, 
was dissolved in methanol. Dry dichloromethane was 
added to this solution followed by the addition of 1 µL 
of trifluoroacetic acid to eliminate Boc. The mixture 
was incubated in shaker for an hour. Solid sodium 
bicarbonate was added to the mixture, to eliminate 
trifluoroacetic acid from the solution, and shake for 
15 min and the supernatant transferred to another vial. 
Solid sodium bicarbonate was washed twice by adding 
100  μL of methanol each time, joining these superna-
tants to the first one which was transferred to a vial. 
The organic solvent was eliminated by vacuum evapo-
ration and 250  µL of PBS 1× and 1  mg of FITC (dis-
solved in DMSO) was added and incubated overnight. 
The mixture was purified by gel filtration and fractions 
of 500 μL were collected and controlled by TLC. The 
fractions 5–9 were joined and non-covalently bound 
FITC to the dendrimers was eliminated by three cycles 
of washing with distilled water and centrifugation with 
a centrifugal filter (cutoff of 10 KDa, Microcon®) (at 
12,000  rpm by 10  min) [33–37]. Finally, the obtained 
supernatant was lyophilized. According to 1H NMR 
analysis the rest of the fractions (1–4 and 10-end) did 
not correspond to the desired product. This procedure 
was performed five times and the results obtained were 
all the same.
1H NMR spectroscopy
The H1 NMR spectrums were recorded, at 303  K, in 
Bruker DPX-400 (400  MHz) spectrometer, employing 
deuterium oxide (D2O) as solvent. The number of scans 
used to obtain the spectrums was of 64. The chemical 
proton shifts are expressed in ppm (δ) employing TSM 
(tetramethylsilane) as zero.
MALDI‑TOF mass spectrometry
Mass spectrometry was performed on a MALDI-time of 
flight mass spectrometer (Microflex LR, Bruker Daltonik 
Billerica, MS, USA) equipped with a 337  nm Nitrogen 
laser, operated in positive-ion, reflectron mode. Exter-
nal mass scale calibration was performed with Pro-
tein Calibration Standard Mix (Bruker). Acquisition 
was performed with FlexControl software (version 3.4, 
Bruker Daltonik GmbH).
The matrix used in the experiments was 2,5-dihydroxy-
benzoic acid (DHB) with D-(þ)-fucose (1:1).
Dynamic light scattering
The particle size, size distribution and particle charge of 
PAMAM G4.5-piperazinyl-FITC dendrimer was meas-
ured by DLS (Zetasizer Nano ZS, Malvern Instruments, 
UK). Briefly, PAMAM G4.5-piperazinyl-FITC dendrimer 
was dissolved with deionized water and the sample was 
filtered with a 0.22  μm membrane. The data obtained 
were the results of three experiments of 5 measures each. 
Data are expressed as mean ± SD.
Transmission electron microscopy
An aliquot of PAMAM G4.5-piperazinyl-FITC den-
drimer was dropped on a carbon coated-copper grid, 
after 1 min the excess of liquid was removed and the grids 
were stained with uranyl acetate. Imaging was performed 
immediately after air-drying by TEM (JEOL JEM-1010). 
Nanoparticle size measurement was performed by Image 
J and the quantification by PAST version 2,12. The data 
obtained were the results of three experiments.
Release study of FITC from PAMAM G4.5‑piperazinyl‑FITC 
dendrimer
The release study of FITC was made by using a Slide-A-
Lyzer Mini Dialysis unit Plus Float of 10  kDa MWCO 
(Thermo Scientific). Briefly, 100  μL of 2.5  mg/mL of 
PAMAM G4.5-piperazinyl-FITC dendrimer solution was 
introduced in the dialysis unit (inner phase) which was 
immersed in 10 mL of PBS 1× pH =  7.4 (outer phase). 
The FITC release study was made at 37  °C with con-
tinuous agitation of the outer phase. Samples of 100 μL 
were taken from the outer phase at the following peri-
ods of time: 0, 6, 18, 24 and 48  h. After each sampling, 
the outer phase was replenished with 100 μL of PBS 1× 
pH = 7.4. The fluorescence of the initial solution of den-
drimers and of the samples collected was measured in a 
plate reader with excitation and emission wavelengths 
of 495 and 525  nm, respectively. Percentages of FITC 
released were calculated and graphed. The data obtained 
were the results of three experiments and are expressed 
as mean ± SD.
Cytotoxicity
The potential PAMAM G4.5-piperazinyl-FITC den-
drimer cytotoxicity was evaluated in mouse mammary 
tumor cells, 4T1 (ATCC). This study was carried out 
by MTT assay of cell viability, according to the method 
described by Mosmann [54]. Briefly, 5  ×  103 4T1 cells 
were seeded in a 96 well plaque and after 24 h the cells 
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were treated with different concentrations of PAMAM 
G4.5-piperazinyl-FITC dendrimer. The absorbance was 
measured in a plaque reader at 570  nm. The cell viabil-
ity percentages of different treatments were calculated by 
considering the absorbance of control as 100 % viability. 
Presented results correspond to n = 3 performed in trip-
licate and expressed as mean ± SD. There is no significant 
difference between cells treated with different concentra-
tions of PAMAM G4.5-piperazinyl-FITC dendrimer and 
control cells at 24 h (Student′s t test: P < 0.05).
Hemolysis
Hemolysis of PAMAM G4.5-piperazinyl-FITC den-
drimer was assayed according to Prieto et al. [55]. Briefly, 
freshly prepared blood from a healthy dog was centri-
fuged at 2000g for 15 min at 4  °C to separate red blood 
cells from plasma. The plasma was replaced with the 
same volume of PBS 1× pH = 7.4. 200 µL of red blood 
cells were incubated with 5  µM or 50  µM of PAMAM 
G4.5-piperazinyl-FITC dendrimer for 4 or 24 h at 37 °C. 
After the incubation, samples were centrifuged at 2000g 
for 10 min and the supernatant absorbance was measured 
at 414  nm with NanoDrop1000 (Thermo). Hemolysis 
was expressed as a percentage of the hemoglobin release 
induced by SDS 2 %. The data obtained were the results 
of three experiments and are expressed as mean ± SD.
Cell uptake
For uptake studies, 5 × 103 4T1 cells were growth on cov-
erslips for 24 h. After this period, cells were treated with 
10 μg/mL of PAMAM G4.5-piperazinyl-FITC dendrimer 
and incubated for 24 h at 37 °C and 5 % CO2. Cells were 
washed with PBS 1× and fixed for 15 min with PFA 3 % 
(paraformaldehyde). The cells were counterstained with 
DAPI (1 µg/mL). Cells were mounted (ProLong Antifade 
Kit (P7481) of Molecular Probes-Invitrogen) over slides 
and observed by LCM (laser confocal microscopy) at the 
following wavelengths: 488 and 405 nm.
Ex vivo fluorescence imaging of tumor
The experimental procedures with BALB/c mice, were 
approved by the local ethics committee (CHEA, Uruguay, 
protocol number: 071140-000207-12), in accordance with 
national legislation. A tumor uptake study of PAMAM 
G4.5-piperazinyl-dendrimers was made by the intrave-
nous injection of 15 mg/kg of the nanosystem in BALB/c 
mice with 4T1 tumors. At 24  h post-injection, we went 
on to extract the following organs: heart, liver, spleen, 
lungs, kidneys and tumor. The organs were disposed in a 
petri dish and then inside the fluorescent imaging equip-
ment (In vivo MSF X PRO, Bruker). The fluorescence 
of the before mentioned organs was captured with and 
excitation and emission wavelength of 480 and 535 nm, 
respectively.
Tumor section analysis by LCM
After 24  h post-injection of PAMAM G4.5-piperazinyl-
FITC dendrimers in mice, the tumor was fixed with PFA 
3 % for 1 h, thoroughly washed and cryoprotected with 
15 and 30  % sacarose for 1  h, respectively. The sample 
was introduced in freezing medium and stored at −20 °C. 
Tissue sections of 5  µm were obtained with a cryostat 
(Slee Mainz 2 Cryostat Mev), counterstained with DAPI 
and analyzed by LCM by using 405 and 488  nm lasers, 
respectively.
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